key: cord-0693808-iqofjzx5 authors: Crommelin, Daan J.A.; Volkin, David B.; Hoogendoorn, Karin H.; Lubiniecki, Anthony S.; Jiskoot, Wim title: The science is there: key considerations for stabilizing viral vector-based Covid-19 vaccines date: 2020-11-23 journal: J Pharm Sci DOI: 10.1016/j.xphs.2020.11.015 sha: a0ba5e825f86a8a3a5eac8710128249f63ace82c doc_id: 693808 cord_uid: iqofjzx5 Once Covid-19 vaccines become available, 5-10 billion vaccine doses should be globally distributed, stored and administered. In this commentary, we discuss how this enormous challenge could be addressed for viral vector-based Covid-19 vaccines by learning from the wealth of formulation development experience gained over the years on stability issues related to live attenuated virus vaccines and viral vector vaccines for other diseases. This experience has led –over time– to major improvements on storage temperature, shelf-life and in-use stability requirements. First, we will cover work on ‘classical’ live attenuated virus vaccines as well as replication competent viral vector vaccines. Subsequently, we address replication deficient viral vector vaccines. Freeze drying and storage at 2-8°C with a shelf life of years has become the norm. In the case of pandemics with incredibly high and urgent product demands, however, the desire for rapid and convenient distribution chains combined with short end-user storage times require that liquid formulations with shelf lives of months stored at 2-8 °C be considered. In confronting this “perfect storm” of Covid-19 vaccine stability challenges, understanding the many lessons learned from decades of development and manufacturing of live virus-based vaccines is the shortest path for finding promising and rapid solutions. Currently, different types of vaccine technologies are under development to immunize the world population against the SARS-CoV-2 virus. On 13 October 2020, one hundred ninety-nine vaccines were in a preclinical development phase and forty-nine in different phases of clinical development. These include candidate vaccines based on RNA, DNA, replicating and non-replicating viral vectors, inactivated and live attenuated viruses, protein subunits and virus-like particles. 1 Among the promising and front-running candidate Covid-19 vaccines, one can find 57 replication competent and replication deficient viral vector-based and live attenuated virus vaccine candidates from 11 companies. 1 Although not all details on storage conditions can be found in the protocols publicly available, clinical trial materials of viral vector-based Covid-19 vaccine candidates are typically transported and stored in a frozen state (≤ -20 °C), unless sufficient long-term stability data has been generated to justify storage at refrigerator temperatures. By comparison, examination of currently available, commercial live attenuated virus and viral vector vaccines shows they are transported and stored within a controlled cold chain, i.e., at refrigerator (2-8 °C) or sub-zero (≤ -20 °C) temperatures, depending on the type of vaccine (see Table 1 for examples). In 2005 the World Health Organization (WHO) reported a 50% wastage of vaccines, partly because of improper temperature control, e.g., inadvertent exposure to elevated temperatures or freezing of vaccines stored under refrigerator conditions. 2 Globally, a one-to two-dose Covid-19 vaccination program would require about 5-10 billion vaccine doses to be manufactured, distributed, stored and administered. The logistics for storage, transportation and handling of such a high number of doses are an enormous challenge, and success highly depends on the possibility to use existing infrastructure. 3 Storage at refrigerator conditions (2-8 °C) is highly preferred over frozen storage (≤ -20 °C). Whereas frozen storage is frequently employed by manufacturers of vaccines for other diseases, maintaining such an extraordinary high number of units of Covid-19 vaccines at sub-zero temperatures is logistically much more challenging than under refrigerator conditions, particularly during transport and short-term storage at a J o u r n a l P r e -p r o o f distribution center and/or at the site of administration. Therefore, vaccine stability under the chosen storage condition is one of the key attributes to be considered when developing a Covid-19 vaccine and is on the WHO list for prioritization of Covid-19 vaccine candidates. 4, 5 In this commentary, we discuss how this stability challenge for viral vector-based Covid-19 vaccine candidates could be addressed by learning from the wealth of formulation development experience gained over the years on stability issues related to live attenuated virus vaccines and viral vector vaccines for other diseases. This experience has led -over time-to major improvements on shelf-life and storage temperature requirements, e.g., for live attenuated varicella virus-containing vaccines (Varivax) and (ProQuad), 6 Table 1 , one can observe that the stability profile of live attenuated and viral vector vaccines depends on the virus type (e.g., enveloped versus non-enveloped virus) as well as the pharmaceutical dosage form (e.g., lyophilized versus liquid). Although beyond the scope of this commentary, a brief mention of some unique challenges with formulation development of live attenuated virus and viral vector-based vaccine products, compared to protein-based drugs such as monoclonal antibodies, is provided to put into perspective the virus vaccine stability discussion below. Because of their structural complexity and the associated challenges to manufacture viral products at large scale, these preparations contain a mixture of infectious and non-infectious viruses (e.g., full and empty viral capsids). 8 Methods to monitor the potency of a live virus-based vaccine can include determination of viral particles or viral genomes, viral infectivity in cell-based assays, or immune responses in animals. Such assays are the J o u r n a l P r e -p r o o f cornerstone of live virus-based vaccine stability assessments. Yet, at the same time, most of these assays are labor intensive, time-consuming and highly variable, making determination of virus stability profiles more challenging. In addition, clinical determinations of the highest virus dose that is safe and the lowest dose that is efficacious must be established to elucidate the "stability window" of the extent of viral degradation that is acceptable across the shelf life of the vaccine product. 6 Therefore, a scientific understanding of the quality/quantity of viral preparations, clinical determinations of dose levels, and an analytical testing strategy of potency are interrelated key factors to be considered during formulation development of stable live virus-based vaccine products. conditions is possible for both products. 25, 26 The ChAdOx1 nCoV-19 vaccine is formulated with a limited number of standard excipients (i.e., sucrose, histidine, NaCl, MgCl 2 , polysorbate 80, EDTA and ethanol). 25 Zabdeno, one of the two J&J vaccines against Ebola virus that uses the same Ad26 viral vector technology, is formulated as a liquid presentation with stability of 8 months at 2-8 °C (Table 1) 23 . A freeze dried Chinese AdV-5 vector-based Ebola vaccine (Ad5-EBOV) was approved in China in 2017 and can be stored at 2-8 °C for 12 months. 27 Based on the same vector technology, a Covid-19 vaccine candidate has been developed, which is now -supplied in liquid form-tested in Phase II clinical trials. 28 Here we see a development towards a new practice where the vaccine is stable for sufficient periods of time at 2-8 °C to cover the short storage times that can be expected in emergency situations such as the Covid-19 pandemic. 28, 29 According to the clinical protocol, long- The urgent need for Covid-19 vaccines to fight the world-wide pandemic has led to the rapid development of first-generation vaccine candidates that may be less than ideal from a vaccine stability and distribution perspective. In the case of viral vector vaccine candidates, formulation challenges outlined in this commentary can be the focus for development of next-generation vaccine candidates as well as second-generation formulations of the lead vaccine candidates currently in late-phase clinical trials. Improved formulations of virus-based Covid-19 vaccines will lead to better stability profiles (e.g., extending shelf life and transitioning from freezer to refrigerator storage) as well as lowering costs and facilitating widespread distribution (e.g., manufacturing of low-cost, widely available, and conveniently administered vaccine dosage forms). Based on these considerations, the following suggestions to facilitate formulation development of viral vector-based Covid-19 vaccine candidates are provided: • When one is charged to develop a formulation for a viral vector-based Covid-19 vaccine candidate, previous experience with formulation and stabilization of live attenuated virus and replication competent viral vector vaccines, as well as the recently approved replication deficient viral vector vaccines, will provide important guidance. In addition, the wealth of information and physicochemical insights regarding the design of stable formulations for biotherapeutics should also be explored. • Virus stability profiles during storage and administration highly depends on the type of virus. For instance, non-enveloped viruses such as adenoviruses are more stable than enveloped viruses such as measles viruses. This may be an important consideration when assessing different viral vector candidates for vaccine development to fight a pandemic. • With advances in formulation science, highly complex formulations used for older viral vaccines, often with poorly defined excipients, can evolve into more well-defined formulations based on a smaller number of globally accepted, pharmacopeia-grade excipients, very much like those used for formulations of recombinant therapeutic proteins. Such formulations offer the ability to lower costs and improve manufacturing capacity. To this end, multi-dose formulations (e.g., 5-10 doses per vial) would further lower costs and increase availability, although their development may be challenging since they typically require the addition of preservatives (to ensure sterility during multiple withdrawals from a single vial), which may be incompatible with live virus and viral vector vaccines during longterm storage. The addition of preservatives to the diluent used to reconstitute a lyophilized vaccine upon administration is one approach to be considered as described for the smallpox (vaccinia virus) vaccine in national stockpiles (see Table 1 ). • Freeze drying of live attenuated virus and viral vector vaccine formulations to avoid sub-zero (≤ -20 o C) storage conditions and allowing storage at 2-8 °C has become the standard for such vaccines for other diseases than Covid-19. Is there a competitive advantage for freeze dried Covid-19 vaccines that can be stored under refrigerator conditions compared to frozen J o u r n a l P r e -p r o o f liquid products? Yes, however, freeze drying is more expensive and the huge number of product units needed in this Covid-9 pandemic may limit production capacity. In addition, the costs and complexity to the health care provider to store and prepare the lyophilized product for administration, using a separately supplied diluent and related reconstitution procedure, also have to be factored in. In contrast, liquid formulations of Covid-19 vaccines are more economical to produce, but may need to be stored in a freezer which adds to the cost and complicates transport and end-user handling. As mentioned above, in this Covid-19 pandemic, storing liquid formulations at 2-8 °C for a limited number of months may be the short-term solution: 28, 29 fast distribution and fast administration are key words when this option is chosen. It is also possible that different regions will be at different stages of pandemic control at different times, and there may be room for multiple approaches for a given vaccine to meet this global pandemic need. In this context, the extended controlled to clinical outcome. Such assays are easier to establish when a novel vaccine candidate is based on a previously established "platform" vaccine technology, since such test methods can more readily be adapted from already established procedures. Covid-19 tracker Monitoring vaccine wastage at country level, WHO/V&B/03 Covid-19 vaccine delivery faces problems, warns DHL. Financial Times WHO target product profiles for COVID-19 vaccines Criteria for COVID-19 vaccine prioritization Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies Freeze-drying of live virus vaccines: A review Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components. Vaccine Formulation, stability, and delivery of live attenuated vaccines for human use Development of Stable Liquid Formulations for Adenovirus-Based Vaccines Towards ambient temperature-stable vaccines: The identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges Development of a stabilizer for lyophilization of an attenuated duck viral hepatitis vaccine Effect of freezing rates and excipients on the infectivity of a live viral vaccine during lyophilization Freeze-drying foot-and-mouth disease virus antigens. I. Infectivity studies Evaluation of the thermal stability of live-attenuated rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers Study on the stability of 17D-204 yellow fever vaccine before and after stabilization Stability of heat stable, live attenuated rotavirus vaccine (ROTASIIL) Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate Stabilization of live attenuated influenza vaccines by freeze drying, spray drying, and foam drying A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination Zabdeno summary of product characteristics Mvabea summary of product characteristics Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Nonreplicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older Ebola vaccines -Background paper for SAGE deliberations Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Clinical protocol: A randomized, double-blind, placebo-controlled phase II clinical trial of the recombinant novel coronavirus vaccine (adenovirus type 5 vector) in healthy adults aged 18 years and above in China Physical characterization and stabilization of a lentiviral vector against adsorption and freeze-thaw Algorithm-based liquid formulation development including a DoE concept predicts long-term viral vector stability Varivax summary of product characteristics RotaTeq summary of product characteristics Rotavirus vaccine information sheet WHO Rotasiil WHO one dose training package Flumist prescribing information FDA Adenovirus type 4 and type 7 vaccine, live, oral enteric coated tablets prescribing information FDA Adenovirus vaccines ACAM2000 prescribing information FDA Stamaril summary of product characteristics Polio Sabin One and Three (oral) WHO package insert Summary of product characteristics Dengvaxia summary of product characteristics Japanese Encephalitis Vaccine (Live) (4 dose vial) WHO package insert Current and new rotavirus vaccines Extended Controlled Temperature Conditions (ECTC) Evaluation of the stability of measles vaccine out of the cold chain under extended controlled temperature conditions